Finally, the correlation between miR‐515‐5p/MARK4 expression and the outcome of metastatic breast and lung cancer suggests the use of miR‐515‐5p and MARK4 as prognostic molecular biomarkers for metastatic cancer patients. This evidence concerns the gene MARK4 and lung cancer.